August 2021

Contents

Editorial

• HTB: no. 8 – plus HIV and COVID-19 (1 August 2021)

Conference reports

• 11th IAS Conference on HIV Science (IAS 2021)

• IAS 2021: lenacapavir studies show impressive results in naive, extensive drug resistance and potential as PrEP

• IAS 2021: HIV pipeline drugs: CAB/RPV LA, fostemsavir, paediatric dolutegravir, lenacapavir, islatravir, MK-8507 and albuvirtide

• IAS 2021: Proving efficacy of next generation PrEP: counterfactual controls in lenacapavir and islatravir studies

• IAS 2021: WHO report links HIV to 30% increased mortality from COVID-19: based on South African data

• IAS 2021: New demands for better transgender heath care: No data no more

• 13th International Workshop on HIV Paediatrics 2021

• Dolutegravir superior to standard-of-care in young children: results from the ODYSSEY trial

Coinfections and complications

• UK Biobank study finds no link between CMV and cardiovascular disease: HIV not included

HIV prevention and transmission

• Phase 1 HIV mosaic vaccine study launched at Oxford university

On the web

• Ending the HIV epidemic (EHE) in the US

COVID-19: HIV and COVID-19 coinfection

• Antibody responses to Pfizer vaccine in HIV positive people with high CD4 counts

COVID-19: vaccine research

• Third dose of mRNA vaccine improves antibody responses in kidney transplant recipients

• US CDC recommends third vaccine dose in some groups

• Pfizer plans for third dose: questions over population need?

• Efficacy of Oxford/AZ and Pfizer vaccines against Delta variant in the UK

• Results from Novavax phase 3 study in the UK

• WHO approves Chinese vaccines for emergency use

• Selected other vaccine studies

• Efficacy of Chinese CoronaVac vaccine in Chile national programme

COVID-19: investigational drugs

• NHS supports selected use of inhaled budesonide for COVID-19 in people at risk of severe events

• Reviews of ivermectin for COVID-19: no evidence of benefit from RCTs

• RCT shows no impact of azithromycin in reducing symptoms of mild COVID-19

COVID-19: pathogenesis

• Variation in ACE2 levels are not related to outcomes from COVID-19

PDFs

• HTB: no. 8 – plus HIV and COVID-19 (1 August 2021)